Summary
Ninety-six patients with intracranial meningiomas and two with hemangiopericytic variants received a 30-min intravenous infusion of bromodeoxyuridine (BrdUrd), 200 mg/m2, before tumor removal. Excised tumor specimens were stained by the indirect immunoperoxidase method to determine the BrdUrd labeling index (LI), or percentage of cells in DNA synthesis. The BrdUrd LI was < 1% in 63 (86.3%) of 73 nonmalignant meningiomas and < 1% in 20 (87%) of 23 malignant meningiomas. Of 23 malignant meningiomas 11 were recurrent tumors; 8 patients had recurrence 3 to 33 months after the study. The recurrence rate was 100% (five of five) in patients whose tumors had a BrdUrd LI > 5%, 44% (11 of 25) in those with a BrdUrd LI 1% to 5%, and 6.1% (4 of 66) in those with an LI < 1%. Thus, meningiomas with a BrdUrd LI > 1% may grow faster and recur more frequently. Among patients with malignant mengngiomas, the mean time to recurrence after the study was 7.5 months in those with a BrdUrd LI > 5% and 20.2 months for those with an LI 1% to 5%. The mean time to recurrence was 97.8 months in patients with nonmalignant meningiomas. Both hemangiopericytic variants were recurrent and showed LIs of 0.5% and 4.1%; the former tumor recurred 8 years after complete resection, while the latter recurred three times in 3.5 years. Thus, the proliferative potential of intracranial meningiomas as reflected by the BrdUrd LI appears to be a prognostic variable that can help to elucidate the biological behavior of individual meningiomas.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adegbite AB, Khan MI, Paine KWE, Tan LK (1983) The recurrence of intracranial meningiomas after surgical treatment. J Neurosurg 58:51–56
Ahyai A, Spaar FW (1987) DNA and prognosis of meningiomas: a comparative cytological and fluorescence-cytophotometrical study of 71 tumors. Acta Neurochir (Wien) 87:119–128
Alvarez F, Roda JM, Morales C, Sarmiento MA, Blazquez MG (1987) Malignant and atypical meningiomas: a reappraisal of clinical, histological, and computed tomographic features. Neurosurgery 20:688–694
Barbaro NM, Gutin PH, Wilson CB, ShelineGE, Boldrey EB, Wara WM (1987) Radiation therapy in the treatment of partially resected meningiomas. Neurosurgery 20:525–528
Carella RJ, Ransohoff J, Newall J (1982) Role of radiation therapy in the management of meningioma. Neurosurgery 10:332–339
Cho KG, Hoshino T, Nagashima T, Murovic JA, Wilson CB (1986) Prediction of tumor doubling time in recurrent meningiomas. J Neurosurg 65:790–794
Crompton MR, Gautier-Smith M (1970) The prediction of recurrence in meningiomas. J Neurol Neurosurg Psychiatry 33:80–87
de la Monte SM, Flickinger J, Linggood RM (1986) Histopathologic features predicting recurrence of meningiomas following subtotal resection. Am J Surg Pathol 10:839–843
Di Chiro G, Hatazawa J, Katz DA, Rizzoli HV, De Michele DJ (1987) Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study. Radiology 164:521–526
Dietemann JL, Heldt N, Burguet JL, Medjek L, Maitrot D, Wackenheim A (1982) CT findings in malignant meningiomas. Neuroradiology 23:207–209
Fukui M, Iwaki T, Sawa H, Inoue T, Takeshita I, Kitamura K (1986) Proliferative activity of meningiomas as evaluated by bromodeoxyuridine uptake examination. Acta Neurochir (Wien) 81:135–141
Gratzner HG (1982) Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: a new reagent for detection of DNA replication. Science 218:474–476
Hoshino T, Nagashima T, Cho KG, Murovic JA, Hodes JE, Wilson CB, Edwards MSB, Pitts LH (1986) S-phase fraction of human brain tumors in situ measured by uptake of bromodeoxyuridine. Int J Cancer 38:369–374
Hoshino T, Nagashima T, Murovic JA, Wilson CB, Davis RL (1986) Proliferative potential of human meningiomas of the brain: a cell kinetic study with bormodeoxyuridine. Cancer 58:1466–1472
Inoue H, Tamura M, Koizumi H, Nakamura M, Naganuma H, Ohye C (1984) Clinical pathology of malignant meningiomas. Acta Neurochir (Wien) 73:179–191
Ironside JW, Battersby RDE, Larwy J, Loomes RS, Day CA, Timperley WR (1987) DNA in meningioma tissues and explant cell cultures. J Neurosurg 66:588–594
Iwaki T, Takeshita I, Fukui M, Kitamura K (1987) Cell kinetics of the malignant evolution of meningothelial meningioma. Acta Neuropathol (Berl) 74:243–247
Jaaskelainen J (1986) Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. Surg Neurol 26:461–469
Jellinger K, Slowik F (1975) Histological subtypes and prognostic problems in meningiomas. J Neurol 208:279–298
Kochanek S, Schroder R, Firsching R (1986) Hemangiopericytoma of meninges. I. Histopathological variability and differential diagnosis. Zbl Neurochir 47:183–190
Ludwin SK, Rubinstein LJ, Russel DS (1975) Papillary meningioma: a malignant variant of meningioma. Cancer 36:1367–1373
Mark JM (1977) Chromosomal abnormalities and their specificity in human neoplasms: an assessment of recent observations by banding techniques. Adv Cancer Res 24:165–222
Marks SM, Whitwell HL, Lye RH (1986) Recurrence of meningiomas after operation. Surg Neurol 25:436–440
Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL (1985) Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg 62:18–24
Nagashima T, De Armond SJ, Murovic J, Hoshino T (1985) Immunocytochemical demonstration of S-phase cells by antibromodeoxyuridine monoclonal antibody in human brain tumor tissues. Acta Neuropathol (Berl) 67:155–159
Pavelic ZP, Allen LM, Mihich E (1981) The relationship of blood vessel proximity and time after radiolabeled thymidine administration to tumor cell population kinetics in a transplanted mouse mammary tumor. Am J Pathol 102:84–89
Roggendorf W, Schuster T, Pfeiffer J (1987) Proliferative potential of meningiomas determined with the monoclonal antibody Ki-67. Acta Neuropathol (Berl) 73:361–364
Russell DS, Rubinstein LJ (1977) Pathology of tumours of the central nervous system, edn 4. Edward Arnold, London, 65–100
Rutka JT, Giblin J, Dougherty DV, McCulloch JR, DeArmond SJ, Rosenblum ML (1986) An ultrastructural and immunocytochemical analysis of leptomeningeal and meningioma cultures. J Neuropathol Exp Neurol 45:285–303
Schröder R, Firsching R, Kochanek (1986) Hemangiopericytoma of meninges. II. General and clinical data. Zbl Neurochir 47:191–199
Seizinger BR, de la Monte S, Atkins L, Gusella JF, Martuza RL (1987) Molecular genetic approach to human meningioma: loss of genes on chromosome 22. Proc Natl Acad Sci USA 84:5419–5423
Sheline GE (1977) Radiation therapy of brain tumors. Cancer 39 [Suppl]:873–881
Simpson D (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20:22–39
Skullerud K, Loken AC (1974) The prognosis in meningiomas. Acta neuropathol (Berl) 29:337–344
Thomas HG, Dolman CL, Berry K (1981) Malignant meningioma: clinical and pathological features. J Neurosurg 55:929–934
Wara WM, Sheline GE, Newman H, Townsend JJ, Boldrey EB (1975) Radiation therapy of meningiomas. AJR 123:453–458
Author information
Authors and Affiliations
Additional information
Supported in part by grant PDT-159 from the American Cancer Society, by grants CA-13525 and CA-50210 from the National Cancer Institute, and by a gift from the Phi Beta Psi Sorority
Rights and permissions
About this article
Cite this article
Lee, K.S., Hoshino, T., Rodriguez, L.A. et al. Bromodeoxyuridine labeling study of intracranial meningiomas: proliferative potential and recurrence. Acta Neuropathol 80, 311–317 (1990). https://doi.org/10.1007/BF00294650
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00294650